The Viral Vector and Plasmid DNA manufacturing market is estimated to reach USD 4.70 billion by 2030 from USD 686.69 million in 2020, delivering a CAGR of 23.8% through the forecast period.
The Viral Vector and Plasmid DNA manufacturing market is estimated to reach USD 4.70 billion by 2030 from USD 686.69 million in 2020, delivering a CAGR of 23.8% through the forecast period. The market growth is driven by the growing prevalence of genetic diseases, the increasing popularity of gene therapy, along with favorable government investments for advancing healthcare technologies. Viral vector and plasmid DNA technology is used as concentrated medications to address diseases specific to patients.
Viral vectors are modified viruses that act as carriers in gene therapy. The carry delivers new gene” in target cells, without letting it degrade. It is widely used to deliver nucleic acids into the genetic makeup of cells, including lentivirus, retrovirus, adenovirus, herpes simplex virus, and others. On the other hand, DNA has a unique property of self-replication and makes up for the majority of genetic research work, including genetic engineering, recombinant DNA technology, gene therapy, and gene transfer. Plasmids are generally used to manipulate, encode, and propagate genetic information. Viral vectors become powerful tools for delivering this genetic information to target cells. Altering of a plasmid DNA for use with viral vector-mediated delivery in target cells has revolutionized the genetic research field.
Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118298
In 2019, Cobra Biologics was awarded the Industrial Strategy Challenge Fund of USD 3.4 million capital by Innovate UK, Department for Business, Energy & Industrial Strategy for expanding its manufacturing capacities for the commercialization of plasmid DNA & viral vectors products.
Growing demand for genetic therapies for the treatment of diseases such as cancer, heart disease, cystic fibrosis, diabetes, AIDS, hemophilia, neurological diseases, and others have created a heavy demand for viral vector and plasmid DNA manufacturing. Several industry players are scaling up their manufacturing to cater to the growing medical need. For instance, Aldevron, a plasmid DNA manufacturer, announced its plans on 13th August, 2020, to scale up its production capacity to cater to the surging demand of gene therapy. The new facility will be 189,00 sq. ft., which will be an addition to an already existing facility of 70,000 sq. ft, located in North Dakota. The new facility will be operational in 2021 and will increase the overall capacity for plasmid DNA production by ten times.
The outbreak of COVID-19 has also pushed companies in a frenzy to come up with a vaccine, which is driving the demand for viral vector and plasmid DNA manufacturing. This has led several pharma companies to collaborate to meet the growing need to develop vaccines. For instance, a global biopharmaceutical CDMO AGC Biologics has partnered with Novavax, Inc., a leading biotech company developing next-gen vaccines for infectious diseases. Currently, AGC Biologics is preparing to manufacture Matrix-M™, which is a major component of the potential coronavirus vaccine, Novavax.
Factors such as expensive product manufacturing and highly regulated processes for vector production and clinical trials may hamper viral vector and plasmid DNA manufacturing market growth.
Regional Outlook:
In 2020, North America accounted for the largest share of 23.1% of the global viral vector and plasmid DNA manufacturing market share, generating revenue over USD 213.4 Million and is estimated to contribute significantly to the revenue share through 2030. The growth rate can be attributed to advanced health infrastructure and the presence of key industry players in the region.
In 2020, APAC generated over USD 372.8 Million in the global revenue share and is set to record the fastest growth rate at 25.4% over the analysis period.
Related Reports:
- Transfer Membrane Market: https://qyresearchmedical.com/report/transfer-membrane-market-size-share-and-analysis-by-type-pvdf-transfer-membrane-nitrocellulose-transfer-membrane-nylon-transfer-membrane-by-transfer-method-tank-electrotransfer-dry-electrotransfer-semi-dry-st-to-2030/118259
- Organs-on-Chips Market: https://qyresearchmedical.com/report/organs-on-chips-market-size-share-and-analysis-by-type-liver-kidney-lung-heart-intestines-gut-by-offering-product-service-by-application-toxicity-testing-physiological-model-by-end-user-academic-st-to-2030/118258
Application Outlook:
In 2020, the cancer segment held the largest market share and is set to register a major growth rate through 2030.
Market-o-nomics
- The Viral Vector and Plasmid DNA manufacturing market is estimated to reach USD 4.70 billion by 2030 from USD 686.69 million in 2020, delivering a CAGR of 23.8% through the forecast period.
- The market growth is driven by the growing prevalence of genetic diseases, the increasing popularity of gene therapy, along with favorable government investments for advancing healthcare technologies.
- In 2019, Cobra Biologics was awarded the Industrial Strategy Challenge Fund of USD 3.4 million capital by Innovate UK, Department for Business, Energy & Industrial strategy for expanding its manufacturing capacities for the commercialization of plasmid DNA & viral vectors products.
- Growing demand for genetic therapies for the treatment of diseases such as cancer, heart disease, cystic fibrosis, diabetes, AIDS, hemophilia, neurological diseases, and others have created a heavy demand for viral vector and plasmid DNA manufacturing.
- Aldevron, a plasmid DNA manufacturer, announced its plans on 13th August 2020, to scale up its production capacity to cater to the surging demand of gene therapy.
- In 2020, North America accounted for the largest share of around 23.1% of the global viral vector and plasmid DNA manufacturing market share, generating revenue over USD 213.4 Million and is estimated to contribute significantly to the revenue share through 2030.
- In 2020, APAC generated 372.8 Million in the global revenue share and is set to record the fastest growth rate at 25.4% over the analysis period.
- In 2020, the cancer segment held the largest market share and is set to register a major growth rate through 2030.
- Factors such as expensive product manufacturing and highly regulated processes for vector production and clinical trials may hamper viral vector and plasmid DNA manufacturing market growth.
Competitive Landscape:
FUJIFILM Diosynth Biotechnologies, Kaneka Eurogentec S.A, Fin vector, Spark therapeutics, Cobra biologics, Cell and gene therapy catapult, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd, Thermo Fisher Scientific, Inc, 4D Molecular Therapeutics are the major players in the Viral vector and plasmid DNA manufacturing market. Capacity expansion and increasing global reach.
In 2020, Aldevron, a U.S. based plasmid DNA manufacturer, entered into a long-term agreement with a leader in precision genetic medicine for rare diseases treatment, Sarepta Therapeutics, Inc. As per the agreement, Aldevron is liable to supply plasmid DNA to Sarepta for commercial supply as well as its gene therapy clinical trials and.
Capacity expansion:
On 7th August 2020, a clinical-stage gene therapy company, MeiraGTx, announced plans to build a multi-million euro facility at Shannon Free Zone, Ireland. The new facility will be focused on increasing the manufacturing of viral vectors and plasmid DNA for gene therapies. The viral vector manufacturing facility is expected to be operational by the end of 2021, while the plasmid production facility will start operations by the end of 2020.
Similarly, in 2017, Brammer Bio invested over USD 50 million for the expansion of its production capabilities in Boston and Florida.
Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118298
Market segmentation:
This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the industry trends in each of the sub-segments from 2017 to 2030. For the purpose of this study, Reports and Data have segmented the viral vector and Plasmid DNA manufacturing market into product types, workflow type, disease type, application type, end-user type, and region.
By Product (Revenue, USD Million; 2019-2030)
- Plasmid DNA
- Viral Vectors
- Non-viral Vectors
By Workflow (Revenue, USD Million, 2019 - 2030)
- Upstream Processing
- Vector Amplification & Expansion
- Vector Recovery/Harvesting
- Downstream Processing
- Purification
- Fill-finish
By Disease (Revenue, USD Million; 2019-2030)
- Cancer
- Inherited Disorders
- Viral Infections
- Others
By Application (Revenue, USD Million, 2019-2030)
- Antisense, RNAi, & Molecular Therapy
- Vaccinology
By Sales Channel (Revenue, USD Million; 2019-2030)
- Channel sales
- Direct Sales
By End-User (Revenue, USD Million; 2019-2030)
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
By Regional Outlook (Revenue, USD Million; 2019-2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Rest of the world
- Brazil
- Saudi Arabia
- South Africa
- Other Countries
Buy quantitative research Report at discounted price - USD 1500 https://qyresearchmedical.com/report/checkout/118298/1500
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
About Us
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL - http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/
https://twitter.com/qyresearchmedi